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Background: Disturbed sleep is strongly correlated with chronic pain. The aim of this study 
was to examine the association between sleep disturbance and incident joint pain focusing on 
neuropathic-like pain symptoms. 
Methods: A total of 423 individuals who had undergone total joint replacement (TJR) for 
osteoarthritis were assessed at the mean time of 3.6 years post-surgery and again at 5.9 years 
post-TJR, using the Medical Outcomes Survey sleep subscale, Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC), and painDETECT questionnaire instruments. Cox 
hazard ratios (HRs) and 95% confidence intervals (CIs) were computed adjusting for age, body 
mass index, sex, and use of hypnotic and analgesic medication. 
Results: The presence of neuropathic pain symptoms predicted incidence of disturbed sleep 
after adjustment for covariates and pain severity (adjusted HR [aHR] 2.01, 95% CI: 1.00–4.10; 
p<0.05). There was no association between joint pain and incidence of disturbed sleep when 
individuals with neuropathic pain symptoms at the baseline visit were excluded (aHR 1.11, 95% 
CI: 0.47–2.67). Disturbed sleep at baseline predicted incident neuropathic joint pain symptoms 
(aHR 2.75, 95% CI: 1.21–6.26; p<0.016) but had no effect on incidence of joint pain when all 
types of pain were considered together (aHR 0.63, 95% CI: 0.30–1.39). 
Conclusion: These data suggest a causal bidirectional link between sleep disturbance and joint 
pain with neuropathic features but not with other types of joint pain.
Keywords: total joint replacement, opioids, osteoarthritis
Plain language summary
Why was the study done?
People experiencing long-term pain commonly complain of disturbed and insufficient quality 
sleep, which is associated with high blood pressure, type 2 diabetes and obesity. Changes in 
the nervous system can cause neuropathic-like pain symptoms, and of 25–30% of people with 
painful osteoarthritis (OA), who have had a total joint replacement (TJR), 25–30% still report 
symptoms of neuropathic pain. This study aimed to discover a possible link between sleep and 
long-term joint pain and if neuropathic-like pain symptoms play a role.
What did the researchers do and find?
A total of 423 people with OA, who had previously undergone TJR, were assessed. In these 
people, a strong link was found between long-term joint pain and disturbed sleep. This increased 
incidence of disturbed sleep linked specifically to neuropathic-like pain symptoms and not 
merely to the presence of pain. The researchers also found that disturbed sleep increases the 
risk of developing new long-term pain in previously pain-free individuals.
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What do these results mean?
In people with OA who have undergone TJR, neuropathic pain can 
predict poor sleep and vice versa. Improving sleep disturbance 
and joint pain has the potential to improve outcomes after joint 
replacement surgery, particularly if pain-relieving strategies target 
neuropathic joint pain.
Introduction
Disturbed sleep is a frequent complaint of people experi-
encing chronic pain such as those with knee osteoarthritis 
(OA).1 The resultant changes in sleep architecture can affect 
health even in the presence of apparently adequate sleep 
duration. For example, an insufficient amount of slow-wave 
sleep associates with hypertension, type 2 diabetes mellitus 
and obesity.2 Sleep disturbances are present in 67–88% of 
people with chronic pain, and ≥50% of individuals with 
insomnia have chronic pain.3 Sleep and pain symptoms are 
considered to be reciprocally interacting.4 Sleep disturbance 
affects nociceptive responses in healthy, pain-free volunteers.5 
Equally, pain affects sleep quality. For example, a prospective 
UK study6 and a recent study from Norway7 have shown that 
widespread pain predicts the incidence of insomnia over a 
3-year period. Furthermore, good sleep improves the long-
term prognosis of individuals with tension-type headache, 
migraine and chronic musculoskeletal pain.4,6
It has been suggested that the hyperalgesic effect of 
sleep deprivation is mediated primarily by impairments in 
the descending pain modulatory systems4,8 rather than by 
amplification of the ascending sensory pathways. A com-
promised pain inhibitory capacity has been demonstrated 
in many idiopathic clinical pain conditions with prominent 
sleep disturbance such as fibromyalgia.9
Total joint replacement (TJR) surgery is a cost-effective 
and safe intervention for severe large-joint OA,10 but the 
health-related quality of life after hip and knee arthroplasty is 
considerably lower than that reported by the general popula-
tion in the same age range.11 More than 20% of individuals 
report moderate to marked persistent pain after 1 year of 
surgery,12 and a substantial proportion of these people also 
report neuropathic-like pain symptoms.13
Neuropathic-like pain symptoms are caused by changes or 
damage to the nervous system, which can result from chronic 
nociceptive input (as seen in chronic pain states) and nerve 
damage during surgery.14,15 Neuropathic pain has been reported 
in people with OA and post-TJR.12,16 Although the majority 
of people with OA do not report neuropathic pain,17,18 reflect-
ing predominantly nociceptive mechanisms in this disease, a 
considerable proportion of them (20–35%) report this type of 
symptoms. Moreover, people with OA who report neuropathic 
pain symptoms are at a greater risk of poor outcome following 
TJR surgery,19 and those with persistent post-arthroplasty pain 
frequently describe neuropathic pain symptoms.13 However, the 
link between disturbed sleep and chronic joint pain, in particular 
neuropathic joint pain, has not been explored to date.
We hypothesized that sleep disturbance in individuals 
with chronic joint pain could be induced by neuropathic pain 
symptoms. In order to explore this, we have examined the 
data collected at two time points, 2 years apart, in a cohort 
of individuals who underwent knee or hip TJR for OA.20
Given the links between descending pain inhibition and 
sleep, we focused in particular on the links between disturbed 
sleep and neuropathic pain seeking to answer two study 
questions: 1) is the link between chronic joint pain and sleep 
mediated by the presence of neuropathic pain symptoms? 
and 2) does sleep disturbance predict the development of 
neuropathic pain symptoms over a 2-year period?
Participants and methods
Study participants
People who had undergone total hip or knee replacement 
surgery were identified from hospital orthopedic clinic lists 
in the Nottinghamshire area, UK, and were mailed an invita-
tion to participate in the study. Approval for the study was 
obtained from the research ethics committees of Nottingham 
City Hospital, North Nottinghamshire, and all participants 
provided written informed consent. Consenting participants 
underwent a home visit by a research nurse between 2008 and 
2012 and completed a nurse-administered questionnaire. A 
total of 615 participants who gave consent to be recontacted 
were sent a follow-up postal questionnaire between 2013 
and 2014; 68% of them returned the full questionnaire, and 
423 individuals who had pain and sleep data at both baseline 
and follow-up were included in the current study. The mean 
(SD) time between TJR and baseline nurse-administered 
questionnaire was 3.6 (2.1) years. The study was originally 
designed to study pain outcomes post-surgery. Having ana-
lyzed these data of the effects seen at year 3, we decided to 
perform a follow-up to provide assessments on how these 
variables changed over time; the meantime for the follow-up 
questionnaire was 5.9 years (2.3 years).
In both the initial nurse-administered questionnaire 
(3.6 years post-surgery) and the second postal questionnaire 
(5.9 years post-surgery), the participants were asked about 
pain, sleep and medication as follows:
Joint pain
The Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) pain score was used. The Likert scale 0 (no 
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pain) to 20 (worst pain) was converted to 0 (worst pain) to 100 
(no pain), and the cutoff definition of “severe” joint pain used by 
Wylde et al12 for post-TJR patients of <50 in this scale was used.
Neuropathic-like pain symptoms at the replaced 
joints (knees or hips)
The painDETECT questionnaire (PDQ) is one of several 
validated instruments for neuropathic pain symptoms. Scores 
range from 0 to 35, with >12 indicating possible neuropathic 
pain and ≥19 indicating likely neuropathic pain.21 Individuals 
were categorized as having possible or likely neuropathic pain 
based on the results of a joint-specific version of the PDQ.21 
The validated PDQ cutoff score of >12 for possible neuro-
pathic pain was used for the presence of neuropathic pain 
symptoms. This score of the PDQ has been shown to correlate 
with sensory abnormalities in OA patients (mechanical gain 
or loss, thermal gain or loss and signs of central sensitization 
measured by quantitative sensory testing) with a 5.6 increased 
risk of showing central sensitization defined as the presence 
of one or more of the following: hyperalgesia to mechanical 
stimuli (pinprick or pressure), a shift in stimulus–response 
curve, mechanical allodynia and/or enhanced temporal 
summation.16 The sensitivity of a PDQ score >12 for central 
sensitization was 50% and the specificity was 74%.16
Sleep questionnaire
The sleep subscale within the Medical Outcomes Survey was 
used to assess sleep quality over the past 4 weeks. The Medical 
Outcomes Study (MOS) Sleep Scale was developed in 1992 for 
the MOS, a study of patients with chronic conditions; hence, it is 
valid to study chronic pain. The instrument can be used to assess 
important aspects of sleep perceived by adults in the general 
population or participating in clinical studies. For example, the 
MOS Sleep Scale has been found to be responsive to change 
in the clinical trial with statistically significant improvements 
observed after administration of pregabalin for sleep distur-
bance, shortness of breath, sleep adequacy, sleep quantity and 
sleep problems.22 The survey uses Likert scales for 10 items 
ranging from “All of the time” to “None of the time”.23,24 We 
recalibrated each subscale to have better sleep corresponding 
to higher values and the sum of scores to 0 (worst sleep) to 
100 (ideal sleep). The bottom tertile of the distribution of sleep 
scores (<60) was used to define disturbed sleep.
Medication use
Individuals were classified as taking opioids, oral nonste-
roidal anti-inflammatory drugs (NSAIDs), anti-neuropathic 
medications and other centrally acting prescription medica-
tions that are used to treat pain and other hypnotics:
•	 Opioids: buprenorphine, co-codamol, codeine, co-
dydramol, co-proxamol, dihydrocodeine, fentanyl, mor-
phine, Nurofen Plus (ibuprofen and codeine phosphate), 
Oramorph, oxycodone, tramadol and Transtec patch 
(buprenorphine).
•	 NSAIDs: celecoxib, diclofenac, meloxicam, naproxen 
and piroxicam. None of the participants reported taking 
other prescription NSAIDs.
•	 Anti-neuropathic medications and other centrally acting 
medication used to treat pain: nefopam, gabapentin and 
pregabalin.
•	 Medications used to treat pain related to central sensitiza-
tion, anxiety, depression and other psychiatric illnesses, 
which may have a hypnotic effect: diazepam, temazepam, 
sertraline, paroxetine, fluoxetine, mirtazapine, venlafax-
ine, amitriptyline, citalopram, dosulepin and duloxetine.
Binary traits
In order to compare hazard ratios (HRs) across the three main 
outcomes, joint pain defined by WOMAC, neuropathic joint 
pain symptoms defined by PDQ and disturbed sleep were 
converted into binary traits using the cutoffs described earlier.
Statistical analysis
We performed a priori power calculations for the two main 
analyses in the study. 1) One of the analyses was the effect 
of sleep disturbance at baseline on predicting onset of pain 
at follow-up (among individuals with no severe pain at 
baseline). Given 288 individuals without disturbed sleep at 
baseline, we estimated the necessary effect size on the inci-
dence of disturbed sleep needed between the 201 individu-
als without severe neuropathic pain and the 86 individuals 
with severe neuropathic pain. We found that an odds ratio 
(OR) of ≥2.1 is needed to achieve ≥80% power with p<0.05 
and an OR of ≥1.8 is needed to achieve 60% power. 2) The 
other analysis was the effect of severe neuropathic pain at 
baseline on developing disturbed sleep at follow-up. Given 
309 individuals without severe pain at baseline, we estimated 
the necessary effect size on incidence of severe pain needed 
between the 185 individuals without disturbed sleep and the 
124 individuals with disturbed sleep at baseline. We found 
that an OR of ≥2.05 is needed to achieve ≥80% power with 
p<0.05 and an OR of ≥1.75 is needed to achieve 60% power.
Mean (SD) and n (%) were used for descriptive purposes 
(Table 1). Longitudinal associations between disturbed sleep 
(dependent variable) were assessed fitting proportional Cox 
regressions, and HRs were used to investigate the associa-
tion between pain at baseline visit and incidence of disturbed 
sleep, and of disturbed sleep at baseline on incidence of joint 
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pain (defined as WOMAC score <50), and neuropathic pain 
symptoms. Cox regression models were fitted including 
age, sex, body mass index (BMI) and use of hypnotic and 
analgesic medication as covariates. All statistical analyses 
were performed using R 3.3.1 (https://cran.r-project.org/).
Results
A total of 423 participants, 59.0% females with mean age 
69 years, participated in this study. Their descriptive character-
istics are given in Table 1. At baseline, 27% of individuals had 
severe joint pain, 24% of them had neuropathic pain symptoms 
and one-third of them fell within the disturbed sleep category.
On cross-sectional analysis, both severe joint pain and 
neuropathic pain symptoms were associated with disturbed 
sleep: adjusted odds ratio (aOR) 9.32 (95% confidence inter-
val [CI]: 5.43–16.02; p<0.0001) and 5.41 (95% CI: 3.27–8.94; 
p<0.0001), respectively, adjusted for age, sex, BMI and use 
of analgesic and hypnotic medications. Both severe pain and 
neuropathic pain symptoms were associated with disturbed 
sleep with aOR 6.1 (95% CI: 3.32–11.2; p<0.0001) and aOR 
2.65 (95% CI: 1.49–4.70; p<0.0009), respectively.
The PDQ and sleep scores at baseline and follow-up 
depending on the presence of neuropathic pain symptoms at 
baseline and disturbed sleep at baseline are given in Table 2. 
A considerable proportion of individuals do not remain in the 
same category (<60% of participants with PDQ score >12 
fall into this category at follow-up).
We first assessed whether pain at the time of first assess-
ment predicted incidence of disturbed sleep at follow-up. We 
did this excluding from the analysis the 31% of individuals 
who already had disturbed sleep at baseline (ie, a sleep score 
<60), thus seeking to identify if there is a relationship between 
incident cases of disturbed sleep at follow-up and pain status 
at baseline. The presence of neuropathic joint pain symp-
toms (affecting 24.4% of individuals at baseline) predicted 
incidence of disturbed sleep over the 2.3-year period with a 
hazard ratio (HR
p
) 2.31 (95% CI: 1.24–4.27; p<0.008; Figure 
1A). This value remained significant after adjustment for 
pain severity (aHR
poor_sleep
 2.01, 95% CI: 1.00–4.10; p<0.05). 
The presence of severe joint pain was also associated with 
the incidence of disturbed sleep (HR
poor_sleep
 2.38, 95% CI: 
1.15–4.96; p<0.02). However, after excluding individuals 
with neuropathic pain symptoms and adjustment for use of 
hypnotic and analgesic medications, this was no longer sig-
nificant (adjusted hazard ratio [aHR] 1.11, 95% CI: 0.47–2.67; 
 Figure 1A), while individuals with neuropathic pain symptoms 
at baseline were at a high risk of developing sleep disturbance 
(aHR 2.31, 95% CI 1.24–4.27; p<0.008) and remained sig-
nificant after adjustment for WOMAC pain scores.
Similarly, being in the bottom tertile of sleep scores 
associated with an increased risk of incident neuropathic 
pain symptoms after 2 years, independent of other covariates 
(aHR 2.75, 95% CI 1.21–6.26; p<0.016). However, being 
in the bottom tertile of sleep scores had no effect on the 
incidence of severe joint pain (HR 2.75, 95% CI 1.21–6.26; 
p<0.016) after adjusting for covariates and medication use 
(Figure 1B).
Discussion
In this longitudinal study, we provided evidence that there is a 
strong temporal link between chronic joint pain and disturbed 
sleep in people who have undergone TJR for OA and also 
Table 1 Descriptive characteristics of study participants, 
including proportion of patients with severe joint pain (WOMAC), 
disturbed sleep (MOS sleep score recalibrated to 0–100) and 
neuropathic joint pain (PDQ) at baseline and follow-up
Trait Value
Participants (N) 423
Sex, female (%) 59.0
BMI (kg/m2), mean (SD) 29.0 (5.2)
Age (years), mean (SD) 69.7 (9.3)
TKR (%) 58.0
THR (%) 36.7
Time of baseline assessment post-surgery (years),  
mean (SD)
3.67 (2.45)
Time from baseline to follow-up in years, mean (SD) 2.33 (1.21)
Baseline pain and sleep
WOMAC pain score (0–100, 100=no pain), mean (SD) 69.62 (23.47)
% of individuals with severe pain (WOMAC score <50) 27.2
PDQ score (0–35, 0=no NP symptoms), mean (SD) 7.36 (7.98)
% of individuals with neuropathic joint pain (PDQ 
score >12)
24.4
MOS sleep score (0–100, 100=no sleep problems), 
mean (SD)
69.58 (17.42)
% of individuals with sleep score <60 31.0
Follow-up pain and sleep
WOMAC pain score (0–100) at follow-up, mean (SD) 71.66 (17.01)
% of individuals with WOMAC score <50 24.84%
PDQ score (0–35) at follow-up, mean (SD) 5.69 (7.80)
% of individuals with possible NP (PDQ>12) at 
follow-up
18.9%
MOS sleep score at follow-up, mean (SD) 66.89 (16.05) 
% of individuals with sleep score <60 32.5%
Use of medication at baseline (%)
Opioids 22.3
Centrally acting medication with possible hypnotic 
effect
8.5
Centrally acting medication used to treat pain 3.5
NSAIDs 7.6
Abbreviations: BMI, body mass index; NSAIDs, nonsteroidal anti-inflammatory 
drugs; MOS, Medical Outcomes Study; NP, neuropathic pain; PDQ, painDETECT 
questionnaire; THR, total hip replacement; TKR, total knee replacement; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.
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showed, to our knowledge for the first time, that the increased 
incidence of disturbed sleep is linked specifically to neuropathic 
pain symptoms and not merely to the presence of pain.
Our data are in agreement with previous prospective stud-
ies that showed that sleep disturbance increases the risk for 
new-onset chronic pain in pain-free individuals, worsens the 
long-term prognosis of existing headache and chronic musculo-
skeletal pain and adversely influences daily fluctuations in pain.4
The bidirectional link that we find between neuropathic 
joint pain and disturbed sleep is consistent with previous 
Table 2 Sleep and PDQ sleep scores at baseline and follow-up in four groups of post-TJR participants
NP  
symptomsa
Disturbed 
sleepb
Participants 
(n)
Baseline Follow-up
MOS score, 
mean (SD)
PDQ score, 
mean (SD)
MOS score, 
mean (SD)
PDQ score, 
mean (SD)
NP  
symptoms (%)a
Disturbed 
sleep (%)b
0 0 275 79.69 (10.24) 3.15 (3.92) 71.62 (13.82) 2.88 (4.85) 5.1 18.2
0 1 74 50.88 (11.63) 5.04 (4.16) 61.42 (16.40) 5.77 (6.97) 17.6 48.7
1 0 43 71.86 (8.38) 18.07 (4.32) 66.67 (15.41) 11.72 (9.88) 53.5 30.2
1 1 71 47.68 (12.62) 19.85 (5.41) 55.85 (14.71) 13.31 (9.58) 55.8 69.0
Notes: aNP symptoms defined from the PDQ score, 0 if PDQ score ≤12 and 1 if PDQ score >12. bDisturbed sleep as defined from the MOS score, 0 if MOS score >60 
and 1 if MOS score ≤60.
Abbreviations: PDQ, painDETECT questionnaire; TJR, total joint replacement; NP, neuropathic pain; MOS, Medical Outcomes Study.
Figure 1 Longitudinal effect of pain on incidence of disturbed sleep and vice versa in 423 individuals post-TJR.
Notes: (A) The effect of different types of pain categories (severe OA pain, NP, severe pain but excluding NP) on the development of disturbed sleep 2 years later in 
individuals in the top two tertiles for sleep score at baseline. Severe joint pain is defined as WOMAC score <50; presence of NP symptoms is defined as PDQ score >12. 
*Model includes age, sex, BMI, severe joint pain and NP. All individuals with disturbed sleep at baseline are excluded from the analysis. (B) Risk of developing different types 
of pain (NP symptoms or moderate to severe joint pain) among individuals who neither had severe joint pain (WOMAC score >50) nor NP symptoms (PDQ ≤12) at baseline 
depending on their sleep disturbance status (bottom tertile of the sleep scores). Individuals with severe pain or NP at baseline were excluded from the analysis.
Abbreviations: TJR, total joint replacement; OA, osteoarthritis; NP, neuropathic pain; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; PDQ, 
painDETECT questionnaire; BMI, body mass index; ns, not significant; HR, hazard ratio.
0.2 0.5 1 2
Hazard ratio for developing severe or NP pain
5 10
Severe pain
Effect of pain on incidence of disturbed sleep
Effect of sleep disturbance on incidence of joint pain
HR (95% CI): 2.38 (1.15, 4.96)
p<0.02
HR (95% CI): 2.31 (1.24, 4.27)
p<0.008
HR (95% CI): 1.11 (0.47, 2.67)
ns
521
Hazard ratio for developing disturbed sleep
A
B
0.5
Severe pain
but no NP
Disturbed sleep
Disturbed sleep HR (95% CI): 2.75 (1.21, 6.26)
p<0.016
HR (95% CI): 0.63 (0.30, 1.39)
ns
severe pain
NP pain
NP pain*
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experimental works showing that there are common brain 
areas involved in both processes. Specifically, the frontal 
cortex and the hippocampus have been implicated both 
in response to sleep deprivation25 and in the processing of 
neuropathic pain26 in animal models. These are also areas 
involved in the negative effect, in particular depression and 
depressive symptoms, which have been shown to be impor-
tant in linking sleep disturbance to pain in OA.1 We did not 
explore this additional affective dimension in the present 
analysis but have adjusted for the use of medications used 
to treat anxiety, depression and other psychiatric conditions.
Our data suggest that pain with neuropathic features and 
disturbed sleep augment each other in a vicious circle. Thus, 
addressing neuropathic pain symptoms might prevent sleep 
disturbances, and interventions addressing sleep disturbance 
should prevent the onset of neuropathic joint pain. Further 
randomized controlled trials are needed to test this theory, 
as both chronic pain and sleep disturbance are common 
prevalent conditions.6,27 We note several study limitations. 
First, our data are from a cohort recruited from secondary 
care and all participants had already undergone TJR surgery 
at the time of baseline assessment. Our findings should be 
generalized to other forms of joint pain in other settings 
with caution. Second, the sleep assessment was self-reported 
in questionnaires. More objective measures such as actig-
raphy or polysomnography might help determine whether 
the associations that we report are explained by alterations 
in sleep or in participant perceptions of sleep quality. In 
addition, we have classified sleep disturbance according to 
tertiles of questionnaire scores within our study population. 
Different results might have been obtained if clinical cutoffs 
were available defining troublesome or pathological sleep 
disturbance. Notwithstanding these caveats, to our knowl-
edge, this is the first study on joint pain that demonstrates 
the bidirectionality of association between sleep disturbance 
and chronic joint pain, specifically addressing the role of 
neuropathic joint pain.
Conclusion
Our study shows that neuropathic joint pain predicts inci-
dence of poor sleep and vice versa in people with OA who 
have undergone TJR. These data suggest a causal bidirec-
tional link between sleep disturbance and neuropathic joint 
pain but not with joint pain in general. Ameliorating sleep 
disturbance and joint pain has potential to improve outcomes 
in people after joint replacement surgery, particularly if 
analgesic strategies target neuropathic joint pain.
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